Demand for COVID-tests (account for nearly 50% of its total revenue) will continue with the lower vaccination rate in its operating countries and increasing incoming foreign tourists.
Increasing contribution from high-value house calls, walk-in patients, and radiology services should act as margin drivers for the company, amid recovery of conventional test revenue at IDH.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.